Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-037-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
There are two key studies for the hydrotrope category substances, both conducted on sodium xylene sulphonate. The key studies are 2-year rat and mouse dermal exposure studies conducted under GLP. Up to 240 mg (rats) and 727 mg (mice) sodium xylenesulfonate/kg body weight in 50% ethanol were dosed 5 days per week for 104 weeks. There were no treatment related incidences of mononuclear cell leukaemia, neoplasms, or non-neoplastic lesions of the skin and other organs. The increased incidence of epidermal hyperplasia may have been related to exposure to the test substance. The NOAEL for systemic toxicity and carcinogenicity was reported as 240 mg/kg bw/day for rats and 727 mg/kg bw/day for mice. The NOAEL for local effects is considered to be 60 mg/kg bw/day, based on the findings from the rat study.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Link to relevant study records
- Endpoint:
- carcinogenicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- December 20, 1990 to December 18, 1992
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Protocols and results reviewed and accepted by the National Toxicology Program's Board of Scientific Counselor's Reports Review Subcommittee. USA National Institutes of Health
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- Deviations:
- not specified
- GLP compliance:
- yes
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: Simonsen Laboratories, Inc (Gilroy, CA)- Age at study initiation: 7 weeks- Weight at study initiation: no data- Fasting period before study: no data- Housing: individually caged in polycarbonate cages changed once per week and rotated on stainless steel racks once every two weeks. Sani-chip hardwood chips and spun-bonded polyester cage filters. - Diet (e.g. ad libitum): ad libitum- Water (e.g. ad libitum):ad libitum- Acclimation period: 14 daysENVIRONMENTAL CONDITIONS- Temperature (°C): 16.7 to 25.6- Humidity (%): 34 to 69- Air changes (per hr): 10 minimum- Photoperiod (hrs dark / hrs light): 12 / 12IN-LIFE DATES: From: December 20, 1990 To: December 18, 1992
- Route of administration:
- dermal
- Vehicle:
- ethanol
- Details on exposure:
- TEST SITE- Area of exposure: shaved interscapular skin- % coverage: no data- Type of wrap if used: no data - Time intervals for shavings or clipplings: no dataREMOVAL OF TEST SUBSTANCE- Washing (if done): no data- Time after start of exposure: no dataTEST MATERIAL- Amount(s) applied (volume or weight with unit): 46 to 128 microliters- Concentration (if solution): 50% of applied volume. Doses were 0, 182, 364 and 727 mg/kg bw- Constant volume or concentration used: yesVEHICLE- Justification for use and choice of vehicle (if other than water): test material beads up in distilled water- Amount(s) applied (volume or weight with unit): in the 46 to 128 microliters- Concentration (if solution): 50%- Lot/batch no. (if required): no data- Purity: no dataUSE OF RESTRAINERS FOR PREVENTING INGESTION: no data
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dose formulations were prepared every 2-3 weeks. HPLC at the beginning of the study and every 7-10 weeks thereafter.
- Duration of treatment / exposure:
- 2 years
- Frequency of treatment:
- 5 days per week
- Remarks:
- Doses / Concentrations:0, 182, 364 and 727 mg/kg bwBasis:analytical conc.
- No. of animals per sex per dose:
- 50
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: based on 17-day and 14-week range finding studies- Rationale for animal assignment (if not random): random
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes - Time schedule: twice daily- Cage side observations checked not in tableDETAILED CLINICAL OBSERVATIONS: Yes - Time schedule: monthlyDERMAL IRRITATION (if dermal study): Yes - Time schedule for examinations: monthlyBODY WEIGHT: Yes - Time schedule for examinations: weekly through week 13 and montly thereafterFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): - Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data - Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No dataFOOD EFFICIENCY:- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No dataWATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not a drinking water studyOPHTHALMOSCOPIC EXAMINATION: No dataHAEMATOLOGY: No dataCLINICAL CHEMISTRY: No dataURINALYSIS: No dataNEUROBEHAVIOURAL EXAMINATION: No dataOTHER:
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 15 ad 16)HISTOPATHOLOGY: Yes (see table 15 and 16)
- Statistics:
- Kaplan-Meier, logistic regression analysis, life table test, FIsher exact test, Cochran-Armitage trend test, comparison of continuous variables, Dunnett and Williams test, Shirley and Dunn
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- OTHER FINDINGS - epidermal hyperplasia observed in males and females at two highest doses and in female controls.
- Relevance of carcinogenic effects / potential:
- No evidence of carcinogenic activity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 727 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: overall effectsclinical signs; mortality; body weight; gross pathology; histopathology
- Remarks on result:
- other:
- Remarks:
- Effect type: other: toxicity and carcinogenicity (migrated information)
- Conclusions:
- Test substance was found to be non-carcinogenic
- Endpoint:
- carcinogenicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- November 29, 1990 to November 20, 1992
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Protocols and results reviewed and accepted by the National Toxicology Program's board of Scientific Counselor's Technical Reports Review Subcommittee, USA National Institutes of Health
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- Deviations:
- not specified
- Principles of method if other than guideline:
- 50 male and 50 female F344/N rats (at 6 weeks old) were administered dermal applications of 0, 60, 120 or 240 mg sodium xylenefulfonate/kg body weight in 50% ethanol. Doses were applied 5 days per week for 104 weeks to the clipped interscapular skin at volumes of 85 to 357 microliters. Volumes were adjusted for the weights of the animals throughout the study. Animals were housed individually and fed and given water ad libitum. Cages were changed weekly and racks were rotated every 2 weeks. All animals were observed twice daily and clinical findings were recorded monthly. Body weights were recorded weekly for 13 weeks, then monthly thereafter. All animals were necropsied and a complete histopathological examination was performed. All organs and tissues including skin were examined for grossly visible lesions. Major tissues were examined microscopically and slides were evaluated by an independent quality laboratory in addition to the study laboratory pathologist. The study was conducted under GLPs. The studywas conducted from November 29, 1990 to November 20, 1992 at the Battelle Columbus Laboratories. The temperature was 20-24.4 degrees centigrade; the humidity was 35-70%; the room air was changed 10 times per hour minimum; and the photoperiod was 12 hours light and 12 hours dark.NTP Technical Report on the Toxicology and Carcinogenesis Studies of Technical Grade Sodium Xylenesulfonate in F344/N Rats and B6C3F1 Mice. NTP TR 464, June 1998. The study reliability is Klimisch 1.
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: Simonsen Laboratories, Inc (Gilroy, CA)- Age at study initiation: 7 weeks- Weight at study initiation: no data- Fasting period before study: no data- Housing: housed individually in polycarbonate cages; changed every week and stainless steel racks rotated every 2 weeks. Heat-treated hardwood chips and spun-bonded polyester cage filters - Diet (e.g. ad libitum): ad libitum- Water (e.g. ad libitum):ad libitum- Acclimation period: 14 daysENVIRONMENTAL CONDITIONS- Temperature (°C): 20-24.4- Humidity (%): 35-70- Air changes (per hr): 10 per day minimum- Photoperiod (hrs dark / hrs light): 12 / 12IN-LIFE DATES: From: November 29, 1990 To: November 20, 1992
- Route of administration:
- dermal
- Vehicle:
- ethanol
- Details on exposure:
- TEST SITE- Area of exposure: shaved interscapular skin- % coverage: no data- Type of wrap if used: no data- Time intervals for shavings or clipplings: no dataREMOVAL OF TEST SUBSTANCE- Washing (if done): no data- Time after start of exposure: no dataTEST MATERIAL- Amount(s) applied (volume or weight with unit): 85 to 357 microliters (volume adjusted for weights during the study)- Concentration (if solution): 50% of applied volume; doses were 0, 60, 120 and 240 mg/kg bw- Constant volume or concentration used: yesVEHICLE- Justification for use and choice of vehicle (if other than water): beading of test substance in distilled water- Amount(s) applied (volume or weight with unit): as part of the 85-357 microliters- Concentration (if solution): 50%- Lot/batch no. (if required): no data- Purity: no dataUSE OF RESTRAINERS FOR PREVENTING INGESTION:no data
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- HPLC at the beginning of the study and then every 7 to 10 weeks
- Duration of treatment / exposure:
- 2 years
- Frequency of treatment:
- 5 days per week
- Post exposure period:
- no data
- Remarks:
- Doses / Concentrations:0, 60, 120 and 240 mg/kg bwBasis:analytical conc.
- No. of animals per sex per dose:
- 50
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: based on 17 day and 14 week range finding studies- Rationale for animal assignment (if not random): random
- Positive control:
- no data
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes - Time schedule: twice daily- Cage side observations checked in table were not included. DETAILED CLINICAL OBSERVATIONS: Yes- Time schedule: monthlyDERMAL IRRITATION (if dermal study): Yes - Time schedule for examinations: monthlyBODY WEIGHT: Yes- Time schedule for examinations: weekly through week 13, monthly thereafterFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): - Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes / No / No data - Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No dataFOOD EFFICIENCY:- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No dataWATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not a drinking water studyOPHTHALMOSCOPIC EXAMINATION: No dataHAEMATOLOGY: No dataCLINICAL CHEMISTRY: No dataURINALYSIS: No dataNEUROBEHAVIOURAL EXAMINATION: No dataOTHER:
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 8)HISTOPATHOLOGY: Yes (see appendix A4 and B4)
- Statistics:
- Kaplan-Meier, logistic regression analysis, life table test, FIsher exact test, Cochran-Armitage trend test, comparison of continuous variables, Dunnett and Williams test, Shirley and Dunn
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- OTHER FINDINGS - epidermal hyperplasia at the site of treatment in several females at the two hightest doses and in one control animal
- Relevance of carcinogenic effects / potential:
- No evidence of carcinogenic activity.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 240 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: overall effectsclinical signs; mortality; body weight; gross pathology; organ weights; histopathology
- Remarks on result:
- other:
- Remarks:
- Effect type: other: toxicity and carcinogenicity (migrated information)
- Dose descriptor:
- NOAEL
- Effect level:
- >= 60 mg/kg bw/day
- Sex:
- female
- Basis for effect level:
- other: Epidermal hyperplasia
- Remarks on result:
- other:
- Remarks:
- Effect type: other: local effects on skin (migrated information)
- Conclusions:
- Test substance was found to be non-carcinogenic
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 240 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- Sufficient to meet requirements.
- System:
- other: skin
Justification for classification or non-classification
There was no evidence of carcinogenic activity in two dermal carcinogenicity studies in rats and mice. Therefore there is no justification for hazard classification.
Additional information
50 male and 50 female rats and mice were administered dermal applications of up to 240 mg (rats) and 727 mg (mice) sodium xylenefulfonate/kg body weight in 50% ethanol. Doses were applied 5 days per week for 104 weeks to the clipped interscapular skin at volumes adjusted for the weights of the animals throughout the study. Animals were housed individually and fed and given water ad libitum. Cages were changed weekly and racks were rotated every 2 weeks. All animals were observed twice daily and clinical findings were recorded monthly. Body weights were recorded weekly for 13 weeks, then monthly thereafter. All animals were necropsied and a complete histopathological examination was performed. All organs and tissues including skin were examined for grossly visible lesions. Major tissues were examined microscopically and slides were evaluated by an independent quality laboratory in addition to the study laboratory pathologist. The study was conducted under GLPs from late 1990 to late 1992 at the Battelle Columbus Laboratories. NTP Technical Report on the Toxicology and Carcinogenesis Studies of Technical Grade Sodium Xylenesulfonate in F344/N Rats and B6C3F1 Mice. NTP TR 464, June 1998. The study reliability is Klimisch 1.
Survival of the dosed males and females was similar to that of the control groups and consistent with historical controls.
Mean body weights of dosed males and females were similar to those of the controls throughout and there were no clinical findings considered treatment related in males. In female rats, clinical findings were limited to irritation at the site of application in one control, in 4 at 120 mg/kg bw and in 2 at 240 mg/kg bw. In mice, clinical finding were limited to irritation of the site of application in female controls, and males and females at the 364 and 727 mg/kg bw doses. There were no treatment related incidences of mononuclear cell leukaemia, neoplasms, or non-neoplastic lesions of the skin and other organs. The increased incidence of epidermal hyperplasia may have been related to exposure to the test substance.
Justification for selection of carcinogenicity via dermal route endpoint:
The NOAEL (systemic and local) were lowest in the rat study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.